- 18Volume 5, 2022Apr 20, Issue 2Feb 01, Issue 1
- 17Volume 4, 2021Dec 13, Issue 21Nov 18, Issue 20Expanding the Potential Benefit of anti-CTLA-4 in Pancreatic Cancer Through a Clinical CollaborationNov 05, Issue 19Sep 22, Issue 18Sep 09, Issue 17Aug 26, Issue 16Jul 20, Issue 14Jun 02, Issue 11May 19, Issue 10May 04, Issue 9Apr 20, Issue 8Apr 06, Issue 7Mar 23, Issue 6Mar 09, Issue 5Feb 23, Issue 4Feb 09, Issue 3Jan 26, Issue 2
- 16Volume 3, 2020Dec 15, Issue 25Dec 01, Issue 24Nov 17, Issue 23Oct 06, Issue 20Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
We are thrilled to be collaborating with @targovax, advancing I-O agents in pursuit of improving safety and outcomes for patients in need twitter.com/targovax/statu…
We’re thrilled to announce a clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial!
— Targovax ASA (@targovax) May 11, 2022
For more information, see https://t.co/CC6TzI3gXl#cancer #immunotherapy #cancerresearch #immunooncology #clinicaltrials
$AGEN Corporate Update and First Quarter 2022 Financial Report investor.agenusbio.com/news-releases/…
The latest $AGEN Newsletter is now available! Here we highlight AGEN1571, our novel antibody targeting ILT2, which we presented data on at #AACR2022. Our IND has been cleared & we expect clinical trials to begin this year. Learn more: agenusbio.com/newsletters/ag…
Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead investor.agenusbio.com/news-releases/…
MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers investor.minktherapeutics.com/news-releases/… Retweeted by Agenus Inc. ($AGEN)
$AGEN featured in the 2022 “Scrip Asks” series where industry executives discuss therapeutic area advances - read @ODayMD discuss how our next-generation CTLA-4 antibody could enhance the possibilities of immunotherapy. @ScripEleanor scrip.pharmaintelligence.informa.com/SC145964/Scrip…
UroGen submits IND application supporting planned Phase 1 clinical study of UGN-301 (zalifrelimab) intravesical solution in recurrent non-muscle invasive bladder cancer investors.urogen.com/news-releases/…
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report investor.agenusbio.com/news-releases/…
Read $AGEN featured in @statnews, where @dhanschand discusses the importance and potential of TGF-beta in I-O, and our anti-TGF-beta program AGEN1423. statnews.com/2022/02/17/tgf…
The latest Agenus newsletter is now available. Agenus is positioned to launch into a year of dynamic advancement in 2022 - with new clinical data, portfolio expansion, and international impact. Read more about our focus on key value drivers in 2022: agenusbio.com/newsletters/ag…
Hear Dr. Steven O’Day join a panel discussion hosted by @Endpts to review the potential of emerging #checkpoint targets at 2pm EST on 1/27! @ODayMD #immunooncology #cancer #lifesciences webinars.endpts.com/the-checkpoint…
Read @garo_armen and other industry leaders express their thoughts on what the future might hold for #immunotherapies in #cancer in this story by @jasonmmast and @endpts. #oncology twitter.com/Jasonmmast/sta…
For the first time since PD-1s were approved, a new kind of checkpoint inhibitor is on its way. That’s big, experts say, but it’s not clear yet what it means for the future of a field thats waited a decade for new breakthroughshttps://t.co/ZMpowcMaTt
— Jason Mast (@Jasonmmast) January 25, 2022
This year, we look forward to accelerating development of our pipeline to broaden the reach of immunotherapies to more patients & tumor types. @omalleygynonc highlights the durable responses induced by our CTLA-4 antibody candidates in many GYN cancers: targetedonc.com/view/sitc-2021…
Bal/Zal Phase 2 cervical cancer trial results published in Journal of Clinical Oncology; 26% ORR (33% ORR in PD-L1+ patients), mDoR not reached after 21 months of follow-up. Click here to read more: investor.agenusbio.com/news-releases/…
$AGEN has been named to the Boston Business Journal’s list of 2021 Middle Market Leaders, their 50 highest growth middle-market companies in MA. We are thrilled to be nominated and look forward to further growth and progress next year. @BosBizJournal bizjournals.com/boston/news/20…
Rottapharm Biotech Clinical Collaboration: An important step for treatment-resistant colorectal cancer The 1st patient has been dosed in their Ph 1/2 study of CR6086 combined with balstilimab in advanced CRC. Read the latest $AGEN newsletter here: agenusbio.com/newsletters/ag…
@dhanschand, $AGEN Scientific Director Head of Drug Discovery, is speaking today at the 2nd Annual TIGIT Therapies Digital Summit on the panel session “Fc binding for Effector Function: What have we Learnt?” Register to watch at 12:30 PM ET! tigit-therapies.com/speaker/dhan-c…
Tune in today at 1:50PM ET for our fireside chat by @garo_armen and @ODayMD at the annual Evercore ISI HealthCONX Conference: wsw.com/webcast/everco…
The latest Agenus Newsletter is now available! AGEN1181 Achieves Responses Across 9 Cancers: Seventeen Objective Responses as Single Agent or in Combination with Balstilimab agenusbio.com/newsletters/ag…
Tune in today to hear @dhanschand and @ODayMD at the B. Riley Fall 2021 Growth Biotech Best Ideas Series, including the latest #AGEN1181 clinical data from #SITC21 investor.agenusbio.com/events/event-d…
